SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about approval for NDA

21 Dec 2018 Evaluate

Sun Pharmaceutical Industries has informed that the U.S. Food and Drug Administration (USFDA) has granted approval for the New Drug Application (NDA), to a wholly owned subsidiary of the company, for ElepsiaTM XR 1000 mg (levetiracetam 1000 mg) and ElepsiaTM XR 1500 mg (levetiracetam 1500 mg). This product was filed from the company’s  Halol (Gujarat, India) facility. The company’s wholly owned subsidiary had in-licensed ELEPSIATM XR from Sun Pharma Advanced Research Company  (SPARC) in July 2016.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Inds. Share Price

1669.95 1.95 (0.12%)
21-Apr-2026 09:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1242.75
Cipla 1230.00
Zydus Lifesciences 935.00
Lupin 2337.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×